Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 11:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 207 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Tetrahydrocannabinol Clear all
Recruiting Phase 2 Interventional Accepts healthy volunteers

Pregnenolone as a Treatment for Cannabis Intoxication

NCT07216690
View directory record Official record
Conditions
Cannabis Intoxication
Interventions
Cannabis, Pregnenolone 250 mg, Pregnenolone 500 mg, Placebo, Placebo brownie
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 29, 2026, 11:23 AM EDT
Recruiting Phase 2 Interventional

Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype

NCT05269628
View directory record Official record
Conditions
Multiple Sclerosis, Sleep, Pain
Interventions
Cannabidiol (CBD), Tetrahydrocannabinol (THC), Placebo CBD, Placebo THC
Drug
Lead sponsor
Tiffany J. Braley, MD, MS
Other
Eligibility
18 Years to 65 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 29, 2026, 11:23 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

The Pharmacokinetics of a Hemp-Based Topical Product

NCT07603518
View directory record Official record
Conditions
Cannabis
Interventions
CBD, THC
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 29, 2026, 11:23 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

The Effects of Cannabis on Male Reproductive Functions

NCT06755346
View directory record Official record
Conditions
Male Reproductive Problem
Interventions
Cannabis plant (THC 20mg), Cannabis (0%/ THC / 0% CBD), Cannabis plant (THC 40mg)
Drug
Lead sponsor
Kanako Hayashi
Other
Eligibility
21 Years to 64 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pullman, Washington
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 29, 2026, 11:23 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Investigation of Psychedelic Effects in Psychoactive Substances

NCT06772753
View directory record Official record
Conditions
Psychedelic Effects in Healthy Volunteers
Interventions
Placebo, Psilocybin, Ketamine, Dextromethorphan (DXM), Dimethyltryptamine (DMT), Methylenedioxymethamphetamine (MDMA), Tetrahydrocannabinol (THC)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
25 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 29, 2026, 11:23 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Synthetic THC And Blood Pressure

NCT07231965
View directory record Official record
Conditions
Blood Pressure
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 40 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 29, 2026, 11:23 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study I

NCT02811510
View directory record Official record
Conditions
Cannabis
Interventions
Placebo, Dronabinol
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 29, 2026, 11:23 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Wayne State Warriors Marijuana Clinical Research Program: Cannabinoid Adjunct to Prolonged Exposure & Recovery

NCT06222268
View directory record Official record
Conditions
PTSD, Post Traumatic Stress Disorder, Suicide, Cannabis Use
Interventions
Cannabidiol (CBD) only, Placebo only, Delta-9-tetrahydrocannabinol (THC) only, THC:CBD 1:1
Drug
Lead sponsor
Leslie Lundahl
Other
Eligibility
18 Years to 60 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 29, 2026, 11:23 AM EDT
Completed Phase 3 Interventional Results available

Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer

NCT01262651
View directory record Official record
Conditions
Pain, Advanced Cancer
Interventions
Nabiximols, Placebo (GA-0034)
Drug
Lead sponsor
GW Pharmaceuticals Ltd
Industry
Eligibility
18 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
25
States / cities
Phoenix, Arizona • El Cajon, California • Gilroy, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 29, 2026, 11:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Responses to Marijuana-Related Cues Versus Neutral Cues in Adults Taking Tetrahydrocannabinol (THC) - 2

NCT00218504
View directory record Official record
Conditions
Marijuana Abuse
Interventions
Tetrahydrocannabinol
Drug
Lead sponsor
Wayne State University
Other
Eligibility
21 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Oct 29, 2026, 11:23 AM EDT
Terminated Phase 4 Interventional Results available

Dronabinol On the Pain Experience

NCT05820685
View directory record Official record
Conditions
Trauma Injury
Interventions
Standard of Care (acetaminophen +naproxen +gabapentin + as needed oxycodone or Tramadol), Dronabinol
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
16 Years to 80 Years
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Oct 29, 2026, 11:23 AM EDT
Recruiting Phase 1 Interventional

Impact of Daily Oral Cannabis Doses in Patients With Cancer

NCT06601218
View directory record Official record
Conditions
Cancer, Cancers, Pain
Interventions
Oral cannabis low THC, Placebo Comparator, Oral cannabis high THC, Oral cannabis THC/CBD
Drug
Lead sponsor
Shanna Babalonis, PhD
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 29, 2026, 11:23 AM EDT
Not yet recruiting Phase 3 Interventional

Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial

NCT07148206
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Dronabinol Capsules, Epidiolex 100 mg/mL Oral Solution, Placebo Dronabinol, Placebo Epidiolex
Drug · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 29, 2026, 11:23 AM EDT
Completed Phase 2 Interventional Results available

Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor Functions in Patients With Irritable Bowel Syndrome (IBS)

NCT01253408
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 7, 2013 · Synced Oct 29, 2026, 11:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Laboratory Model of Increasing Delta-9-tetrahydrocannabinol (THC) Potency on Cigarette Smoking

NCT02961309
View directory record Official record
Conditions
Tobacco Use
Interventions
THC
Drug
Lead sponsor
Battelle Memorial Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 29, 2026, 11:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Clinical Study to Evaluate the Effects of Oral Delta-9-tetrahydrocannabinol (Δ9-THC) With and Without Alcohol on Perception and Driving Performance in Healthy Adults

NCT07176208
View directory record Official record
Conditions
Cannabis, Drug Effects, Driving Performance
Interventions
5 mg Dronabinol (Marinol®) + Placebo Beverage, 10 mg Dronabinol (Marinol®) + Placebo Beverage, 5 mg Dronabinol (Marinol®) + Alcohol Beverage, 10 mg Dronabinol (Marinol®) + Alcohol Beverage, Placebo Capsule + Alcohol Beverage, Placebo Capsule + Placebo Beverage
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
21 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 29, 2026, 11:23 AM EDT
Recruiting No phase listed Observational

Study of an Oral Fluid Testing Approach

NCT06891235
View directory record Official record
Conditions
Cannabis Use, Cannabis Intoxication, Cannabis Use Disorder
Interventions
Biologic testing for THC
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years to 35 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 29, 2026, 11:23 AM EDT
Not listed Phase 2 Interventional

Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea

NCT04091789
View directory record Official record
Conditions
Dysmenorrhea, Headache, Migraine, Fatigue, Nausea, Mood Disturbance
Interventions
Pure Femme Tablets
Drug
Lead sponsor
Pure Green
Industry
Eligibility
21 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Sterling Heights, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 29, 2026, 11:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effect of Lofexidine and Oral THC on Marijuana Withdrawal and Relapse

NCT00373503
View directory record Official record
Conditions
Marijuana Dependence
Interventions
Lofexidine, dronabinol, Marijuana
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Oct 29, 2026, 11:23 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Dronabinol to Treat Obstructive Sleep Apnea

NCT01755091
View directory record Official record
Conditions
Sleep Apnea, Obstructive
Interventions
Dronabinol, Placebo (for Dronabinol)
Drug
Lead sponsor
University of Illinois Chicago
Other
Eligibility
21 Years to 64 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Oct 29, 2026, 11:23 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition

NCT02404688
View directory record Official record
Conditions
Cannabis, Alcohol Effect, Driving Under the Influence of Alcohol and Other Drugs
Interventions
Active delta-9-THC, Placebo, Active Ethanol
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2026
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 29, 2026, 11:23 AM EDT
Completed Phase 1 Interventional

Effects of Delta9-tetrahydrocannabinol (THC) on Retention of Memory for Fear Extinction Learning in PTSD: R33 Study

NCT04080427
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Placebo capsule, Dronabinol 7.5 milligram oral capsule
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 60 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 29, 2026, 11:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?

NCT01964404
View directory record Official record
Conditions
Schizophrenia, Dual Diagnosis, Psychotic Disorder, Cannabis Use Disorder
Interventions
Marijuana, Dronabinol, Placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
263 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
2
States / cities
Lebanon, New Hampshire • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 29, 2026, 11:23 AM EDT
Recruiting Phase 2 Interventional

Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors

NCT06731894
View directory record Official record
Conditions
Breast Carcinoma, Chemotherapy-Induced Peripheral Neuropathy, Colon Carcinoma
Interventions
Biospecimen Collection, Cannabidiol, Dronabinol, Placebo Administration, Survey Administration
Procedure · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 29, 2026, 11:23 AM EDT